Analyst Price Targets — COLL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 10, 2026 2:21 pm | Les Sulewski | Truist Financial | $58.00 | $46.21 | TheFly | Collegium Pharmaceutical price target raised to $58 from $55 at Truist |
| January 9, 2026 12:20 pm | — | Barclays | $56.00 | $48.78 | TheFly | Collegium price target lowered to $56 from $58 at Barclays |
| January 9, 2026 11:10 am | — | H.C. Wainwright | $60.00 | $48.78 | TheFly | Collegium Pharmaceutical price target raised to $60 from $46 at H.C. Wainwright |
| January 7, 2026 12:21 pm | — | Truist Financial | $55.00 | $46.21 | TheFly | Collegium Pharmaceutical price target raised to $55 from $47 at Truist |
| December 8, 2025 9:25 pm | — | Barclays | $58.00 | $47.91 | TheFly | Collegium Pharmaceutical initiated with an Overweight at Barclays |
| February 4, 2025 11:38 am | David Amsellem | Piper Sandler | $36.00 | $30.93 | TheFly | Collegium Pharmaceutical price target lowered to $36 from $37 at Piper Sandler |
| November 11, 2024 8:55 pm | Glen Santangelo | Jefferies | $40.00 | $32.18 | StreetInsider | Collegium Pharmaceutical (COLL) PT Lowered to $40 at Jefferies |
| September 4, 2024 12:25 pm | Oren Livnat | H.C. Wainwright | $50.00 | $38.65 | TheFly | Collegium Pharmaceutical price target raised to $50 from $47 at H.C. Wainwright |
| August 9, 2024 9:15 am | David Amsellem | Piper Sandler | $37.00 | $34.63 | StreetInsider | Collegium Pharmaceutical (COLL) PT Lowered to $37 at Piper Sandler |
| July 30, 2024 6:12 am | Oren Livnat | H.C. Wainwright | $47.00 | $38.60 | StreetInsider | H.C. Wainwright Upgrades Collegium Pharmaceutical (COLL) to Buy |
Latest News for COLL
Collegium Pharmaceutical (NASDAQ: COLL) outlined its 2026 outlook and discussed its planned acquisition of the ADHD treatment AZSTARYS during a fireside chat at Needham and Company's 25th Annual Healthcare Conference. President and CEO Vikram Karnani and Chief Financial Officer Colleen Tupper spoke with Needham healthcare analyst Serge Belanger about growth drivers across the company's ADHD and
STOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 25th Annual Needham Virtual Healthcare Conference Fireside Chat Date and Time: Wednesday, April 15, 2026, at 2:15 p.m.
6,224 shares were sold for a transaction value of ~$228,000 on March 9, 2026. This sale represented 6.40% of Dieter David's direct holdings prior to the transaction.
electroCore (NASDAQ: ECOR - Get Free Report) and Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Volatility and Risk electroCore has a beta of
Scott Dreyer sold 49,976 shares on March 3, 2026, for approximately $2.02 million at a weighted average price of about $40.41 per share. The sale reduced Dreyer's direct holdings by 41.05%, from 121,746 shares to 71,770 shares.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for COLL.
U.S. House Trading
No House trades found for COLL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.